AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia — AbCellera Biologics Inc. (Nasdaq: ABCL) (“AbCellera”) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares […]
AbCellera Biologics Inc., a biotechnology company listed on the Nasdaq exchange, has announced the pricing of its oversubscribed public offering of common shares and pre-funded warrants. The offering consists of 17,435,897 common shares, priced at $9.75 each for the public. In addition, certain investors are being offered pre-funded warrants, which allow them to purchase up to 3,076,926 shares of AbCellera's common shares at a price of $9.74999 per warrant.
This warrant price reflects the public offering price per share minus a $0.00001 per share exercise price for each warrant. The gross proceeds estimated from this offering are approximately $200 million, excluding underwriting discounts, commissions, and offering expenses. All of the shares and warrants will be sold directly by AbCellera.
The offering is anticipated to close on August 14, 2026, provided that all necessary conditions are met.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
